A Phase 3 interventional study of RSVPreF3 OA vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Active, not recruiting at 251 sites in 17 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 2nd largest by enrollment, is one of 7 that started in 2024, is one of 15 in phase 3, and was the 12th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 7 started in 2024.
This study's enrollment of 10,212 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 3rd largest by enrollment, is one of 6 that started in 2024, is one of 21 in phase 3, and was the 34th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical Conditions:
Prior/Concomitant Therapy:
Prior/Concurrent Clinical Study Experience:
Other Exclusion Criteria:
Specific exclusion criteria for Crossover group:
Specific exclusion criteria for RSV_PreS4, RSV_PreS5 and RSV_1Dose groups:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive 1 dose of RSVPreF3 OA vaccine before RSV Season 4.
Biological: RSVPreF3 OA vaccine
Participants in this group will receive 1 dose of RSVPreF3 OA vaccine before RSV Season 5.
Biological: RSVPreF3 OA vaccine
Participants in this group will not receive any additional dose of RSV PreF3 OA vaccine.
Participants in this group will receive a single dose of RSVPreF3 OA vaccine.
Biological: RSVPreF3 OA vaccine
RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)
RSV-A neutralizing titers expressed as Geometric mean titers (GMTs) in RSV_PreS4 group at Day 1
Time frame: At Day 1
RSV-A neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 31
Time frame: At Day 31
RSV-B neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 1
Time frame: At Day 1
RSV-B neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 31
Time frame: At Day 31
RSV-A neutralizing titers expressed as Mean geometric increase (MGI) in RSV_PreS4 group
Time frame: From Day 1 to Day 31
RSV-B neutralizing titers expressed as MGI in RSV_PreS4 group
Time frame: From Day 1 to Day 31
Percentage of participants with RSV-A neutralizing titers greater than or equal to (>=) cut-off in RSV_PreS4 group at Day 1
Time frame: At Day 1
Percentage of participants with RSV-A neutralizing titers >= cut-off in RSV_PreS4 group at Day 31
Time frame: At Day 31
Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS4 group at Day 1
Time frame: At Day 1
Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS4 group at Day 31
Time frame: At Day 31
Percentage of participants with seroresponse rate (SRR) for RSV-A neutralizing titers in RSV_PreS4 group
Time frame: At Day 31
Percentage of participants with SRR for RSV-B neutralizing titers in RSV_PreS4 group
Time frame: At Day 31
RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Day 1
Time frame: At Day 1
RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 12
Time frame: At Month 12
RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 13
Time frame: At Month 13
RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 24
Time frame: At Month 24
RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Day 1
Time frame: At Day 1
RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 12
Time frame: At Month 12
RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 13
Time frame: At Month 13
RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 24
Time frame: At Month 24
RSV-A neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 13
Time frame: From Month 12 to Month 13
RSV-A neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 24
Time frame: From Month 12 to Month 24
RSV-B neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 13
Time frame: From Month 12 to Month 13
RSV-B neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 24
Time frame: From Month 12 to Month 24
Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Day 1
Time frame: At Day 1
Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 12
Time frame: At Month 12
Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 13
Time frame: At Month 13
Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 24
Time frame: At Month 24
Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Day 1
Time frame: At Day 1
Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 12
Time frame: At Month 12
Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 13
Time frame: At Month 13
Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 24
Time frame: At Month 24
Percentage of participants with seroresponse rate (SRR) for RSV-A neutralizing titers in RSV_PreS5 group
Time frame: At Month 13
Percentage of participants with SRR for RSV-B neutralizing titers in RSV_PreS5 group
Time frame: At Month 13
RSV-A neutralizing titers expressed as GMTs in RSV_1Dose group
Time frame: At Day 1, Month 12 and at Month 24
RSV-B neutralizing titers expressed as GMTs in RSV_1Dose group
Time frame: At Day 1, Month 12 and at Month 24
Percentage of participants with RSV-A neutralizing titers >= cut-off in RSV_1Dose group
Time frame: At Day 1, Month 12 and at Month 24
Percentage of participants with RSV-B neutralizing titers >= cut-off in RSV_1Dose group
Time frame: At Day 1, Month 12 and at Month 24
Number of participants with unsolicited adverse events
Time frame: At Day 30 post vaccination
Number of participants with any serious adverse events (SAEs)
Time frame: From day of vaccination and up to 6 months post each vaccine administration
Number of participants with SAEs related to study intervention
Time frame: From Day 1 and up to end of study
Number of participants with any potential immune-mediated disease (pIMDs)
Time frame: From day of vaccination and up to 6 months post each vaccine administration
Number of participants with pIMDs related to study intervention
Time frame: From Day 1 and up to end of study
Number of participants with fatal SAEs
Time frame: From Day 1 and up to end of study
Showing the first 100 of 251 sites across 17 countries. Choose a country and city above to see the rest.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Sep 2026, 25 months after the start.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's planned 25 months is above that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →